| scholarly article | Q13442814 |
| P50 | author | Miroslav Zavoral | Q12038029 |
| Paola Gerletti | Q125310587 | ||
| Craig J Eagle | Q125310663 | ||
| P2093 | author name string | Bernard Levin | |
| Nadir Arber | |||
| Maria J Lechuga | |||
| István Rácz | |||
| Neal Collins | |||
| Aurora Breazna | |||
| Julius Spicak | |||
| Rebecca B Rosenstein | |||
| P2860 | cites work | Folic Acid for the Prevention of Colorectal Adenomas | Q22252994 |
| The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results | Q24514937 | ||
| Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. | Q27851408 | ||
| Long-term use of aspirin and nonsteroidal anti-inflammatory drugs and risk of colorectal cancer | Q28188848 | ||
| A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer | Q28195274 | ||
| A randomized trial of aspirin to prevent colorectal adenomas | Q28195296 | ||
| Celecoxib for the prevention of sporadic colorectal adenomas | Q28200368 | ||
| Celecoxib for the prevention of colorectal adenomatous polyps | Q28200375 | ||
| Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial | Q28217835 | ||
| The use of aspirin for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task Force | Q28220086 | ||
| Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2) | Q28586461 | ||
| The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis | Q29616121 | ||
| Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas | Q29620630 | ||
| Five-year efficacy and safety analysis of the Adenoma Prevention with Celecoxib Trial | Q30497323 | ||
| Cyclooxygenase-2 polymorphisms, aspirin treatment, and risk for colorectal adenoma recurrence--data from a randomized clinical trial | Q33503521 | ||
| Aspirin use and survival after diagnosis of colorectal cancer | Q33764480 | ||
| Calcium supplements for the prevention of colorectal adenomas. Calcium Polyp Prevention Study Group | Q34487340 | ||
| Aspirin use and reduced risk of fatal colon cancer | Q34567474 | ||
| Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas | Q34570463 | ||
| A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas. | Q34572357 | ||
| Mechanism of inhibition of tumour growth by aspirin and indomethacin | Q36042640 | ||
| Nonsteroidal anti-inflammatory drug use after 3 years of aspirin use and colorectal adenoma risk: observational follow-up of a randomized study | Q37101384 | ||
| Chemoprevention of colorectal neoplasia: the potential for personalized medicine | Q37131473 | ||
| Cyclooxygenase-2 inhibitors in colorectal cancer prevention: counterpoint. | Q37245579 | ||
| Effects of aspirin on 1, 2-dimethylhydrazine-induced colonic carcinogenesis | Q42451058 | ||
| Inhibitory effect of aspirin on azoxymethane-induced colon carcinogenesis in F344 rats | Q42506541 | ||
| Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials. | Q46124744 | ||
| Aberrant crypt foci in the adenoma prevention with celecoxib trial | Q46166170 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1135-1146 | |
| P577 | publication date | 2011-04-19 | |
| P1433 | published in | The American Journal of Gastroenterology | Q7713501 |
| P1476 | title | Five-year analysis of the prevention of colorectal sporadic adenomatous polyps trial. | |
| P478 | volume | 106 |
| Q34801966 | Application of surface-enhanced laser desorption/ionization time-of-flight mass spectrometry technology for the diagnosis of colorectal adenoma |
| Q22306433 | Aspirin in the Chemoprevention of Colorectal Neoplasia: An Overview |
| Q37233040 | Associations between urinary soy isoflavonoids and two inflammatory markers in adults in the United States in 2005-2008. |
| Q36100952 | Celecoxib and Bcl-2: emerging possibilities for anticancer drug design |
| Q48045186 | Celecoxib for the Prevention of Colorectal Adenomas: Results of a Suspended Randomized Controlled Trial. |
| Q38873392 | Celecoxib increases EGF signaling in colon tumor associated fibroblasts, modulating EGFR expression and degradation. |
| Q35830941 | Celecoxib pathways: pharmacokinetics and pharmacodynamics |
| Q28589784 | Chemoprevention of colorectal cancer in individuals with previous colorectal neoplasia: systematic review and network meta-analysis |
| Q41979457 | Colorectal adenoma recurrence rates among post-polypectomy patients in the placebo-controlled groups of randomized clinical trials: a meta-analysis |
| Q34428950 | Combined therapy with COX-2 inhibitor and 20-HETE inhibitor reduces colon tumor growth and the adverse effects of ischemic stroke associated with COX-2 inhibition |
| Q44399871 | Digestive cancer management in Asia: position statements: a report on GI Oncology Summit in 2011. |
| Q45720383 | Effects of aspirin and non-aspirin nonsteroidal anti-inflammatory drugs on the incidence of recurrent colorectal adenomas: a systematic review with meta-analysis and trial sequential analysis of randomized clinical trials. |
| Q33739788 | Effects of chemopreventive agents on the incidence of recurrent colorectal adenomas: a systematic review with network meta-analysis of randomized controlled trials |
| Q60913184 | Efficacy and safety of celecoxib on the incidence of recurrent colorectal adenomas: a systematic review and meta-analysis |
| Q87985046 | Eicosanoids in platelets and the effect of their modulation by aspirin in the cardiovascular system (and beyond) |
| Q28084346 | Genetics and Genetic Biomarkers in Sporadic Colorectal Cancer |
| Q35619102 | Impact of genetic polymorphisms on adenoma recurrence and toxicity in a COX2 inhibitor (celecoxib) trial: results from a pilot study |
| Q34017114 | Inactivating mutation in the prostaglandin transporter gene, SLCO2A1, associated with familial digital clubbing, colon neoplasia, and NSAID resistance |
| Q36172737 | Inhibition of COX-2 in colon cancer modulates tumor growth and MDR-1 expression to enhance tumor regression in therapy-refractory cancers in vivo |
| Q38571099 | Mesalamine, but Not Sulfasalazine, Reduces the Risk of Colorectal Neoplasia in Patients with Inflammatory Bowel Disease: An Agent-specific Systematic Review and Meta-analysis |
| Q42755952 | Natural Products as a Vital Source for the Discovery of Cancer Chemotherapeutic and Chemopreventive Agents |
| Q42373340 | Nonsteroidal anti-inflammatory drugs (NSAIDs) and prostate cancer risk: results from the EPICAP study. |
| Q36215197 | Oral perfluorooctane sulfonate (PFOS) lessens tumor development in the APCmin mouse model of spontaneous familial adenomatous polyposis. |
| Q35051366 | Pharmacological and dietary prevention for colorectal cancer |
| Q55262561 | Post-trial follow-up methodology in large randomised controlled trials: a systematic review. |
| Q38362344 | Practical opportunities to improve early detection and prevention of colorectal cancer (CRC) in members of high-risk families |
| Q38268526 | The efficacy and safety of non-steroidal anti-inflammatory drugs in preventing the recurrence of colorectal adenoma: a meta-analysis and systematic review of randomized trials |
| Q35656204 | The influence of UGT1A6 variants and aspirin use in a randomized trial of celecoxib for prevention of colorectal adenoma |
| Q37982139 | The role of low-dose aspirin in the prevention of colorectal cancer |
| Q21245755 | Thymoquinone attenuates tumor growth in ApcMin mice by interference with Wnt-signaling |
Search more.